Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLEANVLU/DFU: Aurase Wound Gel in Venous Leg Ulcers and Diabetic Foot Ulcers
2020-001392-32Phase 2Completed
- Sponsor
- SolasCure
- Start
- Sep 2021
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aurase in stasis ulcer, diabetic foot ulcer (DFU) and leg ulcer, sponsored by SolasCure. Primary endpoint: Adverse Events and Serious Adverse Events. Started Sep 2021; status: completed.
02
Drugs
aurase
03
Conditions
stasis ulcerdiabetic foot ulcer (DFU)leg ulcer
Beyond the preview
Go deeper on 2020-001392-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001392-32.